| Market Cap | 2.47M | P/E | - | EPS this Y | 68.50% | Ern Qtrly Grth | - |
| Income | -40.2M | Forward P/E | -0.11 | EPS next Y | 29.40% | 50D Avg Chg | -82.00% |
| Sales | 13.96M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -96.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -100.00% |
| Recommedations | 1.80 | Quick Ratio | 0.50 | Shares Outstanding | 24.75M | 52W Low Chg | 217.00% |
| Insider Own | 10.69% | ROA | -69.84% | Shares Float | 19.68M | Beta | - |
| Inst Own | 56.20% | ROE | - | Shares Shorted/Prior | 0.94M/60.40K | Price | 0.05 |
| Gross Margin | 80.51% | Profit Margin | -291.02% | Avg. Volume | 2,911,943 | Target Price | 7.20 |
| Oper. Margin | -284.67% | Earnings Date | Mar 30 | Volume | 2,737,134 | Change | -31.16% |
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.